Search Results - "Garrigós, Laia"

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond by Perez, Jose, Garrigós, Laia, Gion, Maria, Jänne, Pasi A, Shitara, Kohei, Siena, Salvatore, Cortés, Javier

“…Despite the substantial improvements made in human epidermal growth factor receptor 2 (HER2)-targeted therapies since the approval of trastuzumab more than…”
Get more information

Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer by Oliveira, Mafalda, Garrigós, Laia, Assaf, Juan David, Escrivá-de-Romaní, Santiago, Saura, Cristina

“…Several agents are being developed for advanced HER2-positive breast cancer, such as potent tyrosine kinase inhibitors (TKI) targeting ErbB family receptors,…”
Get full text

Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study by Prieto-Alhambra, Daniel, Servitja, Sonia, Javaid, M. Kassim, Garrigós, Laia, Arden, Nigel K., Cooper, Cyrus, Albanell, Joan, Tusquets, Ignasi, Diez-Perez, Adolfo, Nogues, Xavier

“…Aromatase inhibitor (AI)-related bone loss is associated with increased fracture rates. Vitamin D might play a role in minimising this effect. We hypothesised…”
Get full text

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer by Servitja, Sònia, Nogués, Xavier, Prieto-Alhambra, Daniel, Martínez-García, María, Garrigós, Laia, Peña, María Jesús, de Ramon, Marta, Díez-Pérez, Adolfo, Albanell, Joan, Tusquets, Ignasi

“…Abstract Objective Baseline bone health in postmenopausal women is poorly characterized in prospective series of early breast cancer (EBC) patients candidates…”
Get full text

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial by Pérez-García, José Manuel, Vaz Batista, Marta, Cortez, Patricia, Ruiz-Borrego, Manuel, Cejalvo, Juan Miguel, de la Haba-Rodriguez, Juan, Garrigós, Laia, Racca, Fabricio, Servitja, Sonia, Blanch, Salvador, Gion, María, Nave, Monica, Fernández-Abad, María, Martinez-Bueno, Alejandro, Llombart-Cussac, Antonio, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier, Braga, Sofía

“…Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy…”
Get full text

Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality? by Aran, Andrea, Garrigós, Laia, Curigliano, Giuseppe, Cortés, Javier, Martí, Mercè

“…T cells play a vital role in the anti-tumoural response, and the presence of tumour-infiltrating lymphocytes has shown to be directly correlated with a good…”
Get full text

Analysis of tumor infiltrating CD4+ and CD8+ CDR3 sequences reveals shared features putatively associated to the anti-tumor immune response by Aran, Andrea, Lázaro, Gonzalo, Marco, Vicente, Molina, Elisa, Abancó, Ferran, Peg, Vicente, Gión, María, Garrigós, Laia, Pérez-García, José, Cortés, Javier, Martí, Mercè

“…Introduction Tumor-infiltrating lymphocytes (TILs) have predictive and prognostic value in breast cancer (BC) and exert a protective function against tumor…”
Get full text

Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer by Franco-Mateos, Emma, Souza-Egipsy, Virginia, García-Estévez, Laura, Pérez-García, José, Gion, María, Garrigós, Laia, Cortez, Patricia, Saavedra, Cristina, Gómez, Patricia, Ortiz, Carolina, Cruz, Víctor L, Ramos, Javier, Cortés, Javier, Vega, Juan F

“…The binding activity of various trastuzumab biosimilars versus the branded trastuzumab towards the glycosylated extracellular domain of the human epidermal…”
Get full text

Abstract 993: GDF15 is a candidate circulating biomarker of eribulin response in breast cancer by Bellio, Chiara, Emperador, Marta, Garrigós, Laia, Zamora, Esther, Saura, Cristina, Littlefield, Bruce A., Villanueva, Josep

“…Abstract Microtubule-targeting agents (MTAs) constitute a diverse group of chemical compounds that bind to microtubules and affect their structure and…”
Get full text

Skeletal adverse effects with aromatase inhibitors in early breast cancer: evidence to date and clinical guidance by Servitja, Sonia, Martos, Tamara, Rodriguez Sanz, Maria, Garcia-Giralt, Natalia, Prieto-Alhambra, Daniel, Garrigos, Laia, Nogues, Xavier, Tusquets, Ignasi

“…Aromatase inhibitors (AIs) are routinely used in the adjuvant treatment of women with hormone receptor-positive early breast cancer. Patients who receive AIs…”
Get full text

Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2‐positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012‐07) by Ciruelos, Eva M., Montaño, Alvaro, Rodríguez, César A., González‐Flores, Encarnación, Lluch, Ana, Garrigós, Laia, Quiroga, Vanesa, Antón, Antonio, Malón, Diego, Chacón, Jose I., Velasco, Montserrat, Gonzalez‐Cortijo, Lucía, Jolis, Laura, Echarri, María J., Muñoz, Montse, Pascual, Tomás, Amigo, Yolanda, Casas, Maribel, Carrasco, Eva, Casas, Ana

“…Objective We compared patients’ preferences for intravenous (IV‐t) versus subcutaneous (SC‐t) trastuzumab administration. Methods Phase III, open‐label,…”
Get full text

Abstract PO5-16-12: EFFICACY AND TOLERABILITY OF METRONOMIC CHEMOTHERAPY (mChT) WITH CYCLOPHOSPHAMIDE, METHOTREXATE AND CAPECITABINE (CMX) IN PATIENTS WITH HEAVILY PRETREATED ADVANCED BREAST CANCER. RESULTS FROM A MULTICENTER RETROSPECTIVE STUDY by Saavedra, Cristina, Gion, María, Cortés, Alfonso, Cortez, Patricia, Garrigós, Laia, Pérez-García, José Manuel, Antonarelli, Gabriele, Cortés, Javier

“…Abstract BACKGROUND mChT consists on the administration of repetitive, low doses of chemotherapy drugs and represents an attractive and active therapeutic…”
Get full text

Abstract A036: Identification of secretome-based eribulin biomarkers for breast cancer therapeutics by Bellio, Chiara, Duran, Juan M., Méndez, Olga, Meo-Evoli, Nathalie, Salvans, Cándida, Garrigós, Laia, Zamora, Esther, Saura, Cristina, Littlefield, Bruce A, Villanueva, Josep

“…Abstract Microtubules are major components of the cytoskeleton. They are involved in a wide variety of cell functions including attribution to cell shape,…”
Get full text

Abstract PD4-06: Trastuzumab deruxtecan in patients with HER2[+] or HER2-low-expressing advanced breast cancer and central nervous system involvement: Preliminary results from the DEBBRAH phase 2 study by Batista, Marta Vaz, Cortez, Patricia, Ruiz, Manuel, Cejalvo, Juan Miguel, de la Haba, Juan, Garrigós, Laia, Racca, Fabricio, Servitja, Sonia, Blanch, Salvador, Teruel, Iris, Pérez-García, José Manuel, Gion, María, Nave, Monica, Llombart-Cussac, Antonio, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortes, Javier, Braga, Sofia

“…Abstract Background: Approximately 30% to 40% of patients (pts) with HER2[+] advanced breast cancer (ABC) will develop brain metastases (BM) during the course…”
Get full text

Abstract OT-28-05: Solti-1718 NEREA trial: Neratinib in hormone receptor (HR)-positive/HER2-negative HER2-Enriched (HER2-E) advanced breast cancer (BC) by Saura, Cristina, Ciruelos, Eva, Vidal, Maria, Garrigós, Laia, Margelí, Mireia, Morales, Serafin, Gonzalez-Farré, Xavier, Bofill, Javier Salvador, Blancas, Isabel, Gasent, Joan M, López-Miranda, Elena, Godoy, Ana, Iglesias, Maria, Sánchez-Rovira, Pedro, Hernao, Fernando, Gallegos, Isabel, Pulido, Catarina, Alves, Sara, Branco, Diogo, Passos-Coelho, José, Escrivá-de-Romaní, Santiago, Ferrero-Cafiero, Juan M, Villagrasa, Patricia, Prat, Aleix

“…Abstract Background: HR+/HER2-negative BC represent ∼70% of all newly diagnosed breast tumors. BC is a clinically and biologically heterogenous disease where…”
Get full text

Determinants of concordance in clinically relevant genes (CRG) from synchronously acquired tumor biopsies (tBx) and ctDNA in metastatic breast cancer (MBC) by Oliveira, Mafalda, Ruiz-Pace, Fiorella, Matito, Judit, Perez-Lopez, Raquel, Suñol, Anna, Bellet, Meritxell, Escriva-de-Romani, Santiago, Zamora, Esther, Gomez, Patricia, Garrigós, Laia, Capelán, Marta, Arumí, Miriam, Ortiz, Carolina, Amair-Pinedo, Fabiola, Mancuso, Francesco M, Espinosa-Bravo, Martin, Nuciforo, Paolo, Dienstmann, Rodrigo, Vivancos, Ana, Saura, Cristina

“…Abstract only 1075 Background: NGS in ctDNA from MBC is feasible and results may be informative for patients’ management, especially in non-luminal tumors…”
Get full text

OCTS-03 A MULTICENTER, OPEN-LABEL, SINGLE-ARM, MULTICOHORT PHASE II CLINICAL TRIAL OF TRASTUZUMAB DERUXTECAN IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE AND HER2-LOW ADVANCED BREAST CANCER (ABC) WITH BRAIN METASTASES AND/OR LEPTOMENINGEAL CARCINOMATOSIS (LMC) – THE DEBBRAH STUDY by Vaz-Batista, Marta, Pérez-García, José Manuel, Cortez, Patricia, Garrigós, Laia, Ruiz-Borrego, Manuel, de la Haba-Rodríguez, Juan, de las Heras, Begoña Bermejo, Servitja, Sonia, Racca, Fabricio, Fernández-Abad, María, Blanch, Salvador, Teurel, Iris, Sáenz1, Jose Ángel Garcia, Ortega, Adela Fernandez, Martrat, Griselda, Shimizu, Eileen, Alcalá-López, Daniel, Pérez-Escuredo, Jhudit, Braga, Sofia, Llombart-Cussac, Antonio, Cortes, Javier

“…Abstract The DEBBRAH study (NCT04420598) evaluated the efficacy and safety of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in patients with…”
Get full text

Concordance of genomic alterations (GA) in synchronous tumor biopsies (tBx) and circulating tumor (ct) DNA from metastatic breast cancer (MBC) patients (pts) by Oliveira, Mafalda, Bellet, Meritxell, Suñol, Anna, Ruiz-Pace, Fiorella, Gomez, Patricia, Escrivá, Santiago, Garrigós, Laia, Zamora, Esther, Capelán, Marta, Azaro, Analía, Arumí, Miriam, Ortiz, Carolina, Matito, Judit, Fasani, Roberta, Mancuso, Francesco M, Espinosa, Martin, Nuciforo, Paolo, Dienstmann, Rodrigo, Vivancos, Ana, Saura, Cristina

“…Abstract only…”
Get full text

Abstract PS11-05: Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low Advanced Breast Cancer and Pathologically Confirmed Leptomeningeal Carcinomatosis: Results from Cohort 5 of the DEBBRAH Study by Batista, Marta Vaz, Pérez-García, José Manuel, Garrigós, Laia, García-Sáenz, José Ángel, Cortez-Castedo, Patricia, Racca, Fabriccio, Blanch, Salvador, Ruíz - Borrego, Manuel, Fernández, Adela, Fernández-Abad, María, Iranzo, Vega, Gion, Maria, Martrat, Griselda, Alcalá-López, Daniel, Pérez-Escuredo, Jhudit, Sampayo-Cordero, Miguel, Llombart-Cussac, Antonio, Braga, Sofía, Cortés, Javier

“…Abstract Background: Leptomeningeal carcinomatosis (LMC) occurs in approximately 5-15% of patients (pts) with advanced breast cancer (ABC) and is associated…”
Get full text

Abstract PD7-02: Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial by Pérez-García, José Manuel, Batista, Marta Vaz, Cortez-Castedo, Patricia, Borrego, Manuel Ruiz, Cejalvo, Juan Miguel, de la Haba-Rodríguez, Juan, Garrigós, Laia, Racca, Fabriccio, Servitja, Sonia, Blanch, Salvador, Gión, Maria, Nave, Mónica, Fernández, Adela, Martínez-Bueno, Alejandro, Llombart-Cussac, Antonio, Sampayo-Cordero, Miguel, Malfettone, Andrea, Cortés, Javier, Braga, Sofía

“…Abstract Background: The antibody-drug conjugate trastuzumab deruxtecan (T-DXd) significantly improved survival outcomes of HER2-low advanced breast cancer…”
Get full text